GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Indivior PLC (CHIX:INDVl) » Definitions » Research & Development

Indivior (CHIX:INDVL) Research & Development : £79.4 Mil (TTM As of Mar. 2025)


View and export this data going back to 2014. Start your Free Trial

What is Indivior Research & Development?

Research & Development is the aggregate amount of research and development expenses during the year. Indivior's Research & Development for the three months ended in Mar. 2025 was £17.0 Mil. Its Research & Development for the trailing twelve months (TTM) ended in Mar. 2025 was £79.4 Mil.

Indivior Research & Development Historical Data

The historical data trend for Indivior's Research & Development can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Indivior Research & Development Chart

Indivior Annual Data
Trend Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24
Research & Development
Get a 7-Day Free Trial Premium Member Only Premium Member Only 29.76 39.10 60.75 91.64 84.64

Indivior Quarterly Data
Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25
Research & Development Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 22.04 21.22 16.63 24.52 17.03

Indivior Research & Development Calculation

This is the expense the company spent on research and development.

Research & Development for the trailing twelve months (TTM) ended in Mar. 2025 adds up the quarterly data reported by the company within the most recent 12 months, which was £79.4 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Indivior  (CHIX:INDVl) Research & Development Explanation

If competitive advantage is created by a patent or tech advantage, at some point it will disappear.

High R&D usually dictates high SG&A which threatens the competitive advantage.

Indivior Research & Development Related Terms

Thank you for viewing the detailed overview of Indivior's Research & Development provided by GuruFocus.com. Please click on the following links to see related term pages.

Indivior Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Indivior PLC (CHIX:INDVl) » Definitions » Research & Development
Comparable Companies
LSE:APH LSE:AGY LSE:ANCR LSE:HCM LSE:EAH LSE:STX AQSE:ANA LSE:PXS LSE:CEL LSE:N4P ZTS XTER:MRK NSE:SUNPHARMA TSE:4502 LSE:HLN XSWX:GALD NSE:DIVISLAB HKSE:03692 XSWX:SDZ XTAE:TEVA
Traded in Other Exchanges
INDV:USA INDV:UK 2IVB:Germany
Address
10710 Midlothian Turnpike, Suite 125, North Chesterfield, Richmond, VA, USA, 23235
Website
https://www.indivior.com
Indivior PLC is a specialty and generic drug manufacturing company. The company is focused on the development, manufacture, and sale of prescription drugs for treatment of substance use disorders and other serious mental illnesses. Its products include, Sublocade, Perseris, Suboxone, Opvee among others. The vast majority of Indivior's revenue is generated in the United States, followed by United Kingdom and the rest of the world.

Indivior Headlines

No Headlines